United Therapeutics Corporation Buyback
OLI recorded this information on 3/25/2024
Company: |
United Therapeutics Corporation |
Buyback: |
UTHR buyback |
$Amount Authorized: |
$1,000,000,000 |
Buyback Details: |
United Therapeutics Corporation (NASDAQ:,b,UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics' common stock. This program builds on United Therapeutics' planned $400 million paydown of its revolving credit facility in 2024, of which $100 million was paid down during the first quarter of 2024. To enact the program, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase $1 billion of the company's common stock. |
United Therapeutics is a biotechnology company. Co. markets and sells four commercial therapies in the U.S. to treat pulmonary arterial hypertension: Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin® (treprostinil) Injection (Remodulin); Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, which is approved for treatment of high-risk neuroblastoma, and the Remunity® Pump for Remodulin.
UTHR SEC Filing Email Alerts Service
Open the UTHR Page at The Online Investor »
Company Name: |
United Therapeutics Corp |
Stock buyback: |
UTHR buyback |
Website: |
www.unither.com |
Sector: |
Biotechnology |
Number of ETFs Holding UTHR: |
83 |
Total Market Value Held by ETFs: |
$2.00B |
Total Market Capitalization: |
$11.06B |
% of Market Cap. Held by ETFs: |
18.10% |
|
Open the UTHR Page at The Online Investor (in a new window) »